Tag: Tradjenta
-
Pancreatic Cancer Associated With Use Of Diabetes Medicines In DPP-4 Inhibitor Drug Class
Increased Risk For Patients With Newly Diagnosed Type 2 Diabetes According To Recent Medical Research Study (Posted by Tom Lamb at DrugInjuryWatch.com) Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines is associated…
-
Diabetes Drugs In DPP-4 Inhibitor Class Associated With Almost Two-Times Increased Risk Of Cholangiocarcinoma
Medical Researchers Finding This Rare But Highly Fatal Cancer Call For More Investigation Into New Possible Drug Side Effect (Posted by Tom Lamb at DrugInjuryWatch.com) A recent medical study shows that the…
-
Diabetes Drug Tradjenta Associated With Bullous Pemphigoid, A Chronic Blistering Skin Condition
Bullous Pemphigoid (BP) Is An Auto-Immune Skin Disease Which Can Be Fatal, Particularly In Patients Who Are Debilitated (Posted by Tom Lamb at DrugInjuryWatch.com) Three relatively new medical studies add weight to…
-
DPP-4 Diabetes Drug Side Effects Include Heart Attacks And Strokes As Well As Heart Failure
Onglyza, Nesina, Januvia, and Tradjenta Are Included In This Popular Class Of Type-2 Diabetes Medications (Posted by Tom Lamb at DrugInjuryWatch.com) In April 2016 the FDA took regulatory action by mandating label…
-
Potential Safety Signal: Rhabdomyolysis May Be Linked To Onglyza, Nesina, Januvia, And Other Diabetes Drugs
FDA Was Already Investigating The Dipeptidyl Peptidase IV (DPP-IV) Inhibitor Class Of Diabetes Drugs For Kidney Or Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) According to a new FDA quarterly report,…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With “joint pain that can be severe and disabling”
Label Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced…
-
Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza — Little Is Known About Long-Term Effects
As “Pancreatitis Is On The Pathway Toward Pancreatic Cancer”, Medical Studies Needed To Determine If GLP-1 Diabetes Medications Linked To Cancers Or Malignancies Involving Pancreas (Posted by Tom Lamb at DrugInjuryWatch.com)______________________________________________________________________________ UPDATE: “Cancer of The Pancreas:…